Company Encyclopedia
View More
name
GENOR-B
06998.HK
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC. In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC.
1.290 T
06998.HKMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking10/54
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE2.68%C
    • Profit Margin12.91%B
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY1450.40%A
    • Net Profit YoY105.42%A
    • Total Assets YoY5.90%B
    • Net Assets YoY5.25%B
  • Cash ScoreA
    • Cash Flow Margin774.67%B
    • OCF YoY1450.40%A
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreA
    • Gearing Ratio17.07%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Genor Biopharma to Drop "B" Marker After Merger Completion

    Genor Biopharma to Drop "B" Marker After Merger Completion

    Reuters·
    HK
    06998
    -1.51%
    Reuters·
    HK
    06998
    -1.51%

    Genor Biopharma's Lerociclib Added to China National Reimbursement Drug List

    Genor Biopharma's Lerociclib has been added to China's 2025 National Reimbursement Drug List, effective January 1, 2026. This inclusion aims to enhance patient access and support the drug's commercialization in China.

    Reuters·
    HK
    06998
    -1.51%
    Reuters·
    HK
    06998
    -1.51%

    Genor Biopharma Shareholders to Vote on Merger, Company Name Change, Share Capital Increase, and One-Off Share Option Plan

    Genor Biopharma Holdings Ltd. is seeking shareholder approval for a merger, a company name change, an increase in authorized share capital, and a one-off share option plan. The shareholder meeting will occur after the relevant circular is dispatched. Shareholders are advised to support the proposal.

    Reuters·
    HK
    06998
    -1.51%
    Reuters·
    HK
    06998
    -1.51%

    Genor Biopharma Announces EGM for Merger and Retention Plan Approval

    Genor Biopharma Holdings Limited has announced an Extraordinary General Meeting on December 22, 2025, to discuss and potentially approve a proposed merger and a retention plan. The merger involves issuing shares to target shareholders, and the retention plan requires approval under the Takeovers Code. These resolutions could significantly impact the company’s strategic direction and shareholder value.

    Tip Ranks·
    HK
    06998
    -1.51%
    Tip Ranks·
    HK
    06998
    -1.51%

    Genor Biopharma Holdings Ltd. Announces Date for Extraordinary General Meeting

    Genor Biopharma Holdings Ltd. will hold an extraordinary general meeting on December 22, 2025, in Shanghai. Shareholders will consider resolutions including authorizing a director to execute documents related to the Whitewash Waiver and changing the company's English and Chinese names upon merger. The original content was published by Genor Biopharma via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    06998
    -1.51%
    Reuters·
    HK
    06998
    -1.51%
    © 2025 Longbridge｜Disclaimer